CTOs on the Move

Houston Galveston Institute

www.talkhgi.org

 
Transforming lives and communities with innovative and collaborative therapy, training and research. Company Overview: The Houston Galveston Institute (HGI) is a non-profit organization thatoffers a unique method of collaborative counseling and post-modern therapy to individuals, families and communities of all socioeconomic backgrounds. We base our approach on the belief That the client is the expert on his or her life and Circumstances. Our job, as therapists, is not to dictate treatment, but to shape the process using the values, desires and needs of our clients. Through this collaboration, clients find new solutions and the strength to endure Challenges and Overcome ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.talkhgi.org
  • 2990 Richmond Ave #530
    Houston, TX USA 77098
  • Phone: 713.526.8390

Executives

Name Title Contact Details

Similar Companies

Terra Nova Counseling

Terra Nova Counseling is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cummins, MacFail and Nutry

Cummins, MacFail and Nutry is a Somerville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neotonus Inc

Neotonus Inc is a Marietta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony™ Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony™ Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.